BioHelix Corporation, Beverly MA 01915, USA.
Clin Chim Acta. 2011 Jan 14;412(1-2):79-85. doi: 10.1016/j.cca.2010.09.014. Epub 2010 Sep 18.
The response to the anticoagulant drug warfarin is greatly affected by genetic polymorphisms in the VKORC1 and CYP2C9 genes. Genotyping these polymorphisms has been shown to be important in reducing the time of the trial and error process for finding the maintenance dose of warfarin thus reducing the risk of adverse effects of the drug.
We developed a real-time isothermal DNA amplification system for genotyping three single nucleotide polymorphisms (SNPs) that influence warfarin response. For each SNP, real-time isothermal Helicase Dependent Amplification (HDA) reactions were performed to amplify a DNA fragment containing the SNP. Amplicons were detected by fluorescently labeled allele specific probes during real-time HDA amplification.
Fifty clinical samples were analyzed by the HDA-based method, generating a total of 150 results. Of these, 148 were consistent between the HDA-based assays and a reference method. The two samples with unresolved HDA-based test results were repeated and found to be consistent with the reference method.
The HDA-based assays demonstrated a clinically acceptable performance for genotyping the VKORC1 -1639G>A SNP and two SNPs (430C>T and 1075A>C) for the CYP2C9 enzyme (CYP2C92 and CYP2C93), all of which are relevant in warfarin pharmacogenentics.
华法林抗凝药物的反应受 VKORC1 和 CYP2C9 基因中遗传多态性的极大影响。研究表明,对这些多态性进行基因分型对于减少寻找华法林维持剂量的试验和错误过程的时间非常重要,从而降低药物不良反应的风险。
我们开发了一种用于基因分型影响华法林反应的三个单核苷酸多态性(SNP)的实时等温 DNA 扩增系统。对于每个 SNP,进行实时等温解旋酶依赖性扩增(HDA)反应以扩增包含 SNP 的 DNA 片段。在实时 HDA 扩增过程中,通过荧光标记的等位基因特异性探针检测扩增子。
通过 HDA 方法分析了 50 个临床样本,总共产生了 150 个结果。其中,HDA 方法与参考方法之间的一致性为 148。两个 HDA 方法无法解决的测试结果样本被重复,并发现与参考方法一致。
HDA 方法在基因分型 VKORC1-1639G>A SNP 和 CYP2C9 酶的两个 SNP(430C>T 和 1075A>C)(CYP2C92 和 CYP2C93)方面表现出临床可接受的性能,所有这些都与华法林药物遗传学相关。